Navigation Links
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
Date:4/15/2008

luding InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results observed in animal models of disease will be predictive of results in humans, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...This analysis showed that Multaq(R) (dronedarone) ...h atrial fibrillation or atrial flutter already ...erapy, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-Fir...he data from the ATHENA study were presented today...ean Society of Cardiology,congress 2008, in Munich...
(Date:9/3/2008)...hird Clinical Trial Reconfirms Strong Evidence Pyc...ave Lasting Effect on Joints Following Cessation ...N, N.J., Sept. 3 /- According to the ...the most common type of arthritis,is on the rise....ytotherapy,Research, reveals Pycnogenol(R), bark e...
(Date:9/2/2008)... NEW YORK, Sept. 3 /- Fore...os Almirall, S.A. today announced results from,two... novel long-acting,inhaled anticholinergic for the...lmonary disease (COPD). In both the ACCLAIM/COPD I...and Safety In Moderate to,Severe COPD Patients) st...
(Date:9/2/2008)... September is Prostate Cancer Awarene...Newswire/ -- September is,Prostate Cancer Awarenes...alm Beach announce a revolutionary new way to trea...nt courses of radiation. Prostate cancer is,the mo... Morse CyberKnife CEO, James G. Schwade, M.D., sa...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 1Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 3Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 4Measurements Poor for Assessing Clinical Trials With Children 17915 1Measurements Poor for Assessing Clinical Trials With Children 17915 21 in 4 U S Toddlers Improperly Vaccinated 17913 11 in 4 U S Toddlers Improperly Vaccinated 17913 21 in 4 U S Toddlers Improperly Vaccinated 17913 3Mylan Announces Final FDA Approval for Trandolapril Tablets 17911 1
...)--Apr 10, 2007 - Bentley,Pharmaceuticals, Inc. (N...ay announced that its abstract entitled "Interim,R...er,Pharmacokinetic Study of Intranasal Insulin Sp...ulin R(R)), Injectable Fast-Acting,Insulin (Humalo...e,I Diabetes Mellitus," has been selected for oral...
...2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences I...e,Company,s clinical and preclinical pipeline, inc... export inhibitor programs, at the,2007 Annual Mee...ch,(AACR), being held in Los Angeles, April 14-18,...are as follows. The,location for all poster presen...
Other Medicine Technology:Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 2Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 3Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...f drugs are determined? How drugs are being tested...t happens if the dosages are unwittingly missed? O...ting patients what happens? Who answers these ques...n the U.S.A. has revealed that in many instances a...
Vitamins-The answer to Heart Disease?
...irus in its latest outbreak has claimed around 156...y officials in Kampala. More shocking is the fact...ng doctors & nurses. But what shocked the nation ...rominent doctor spearheading the fight against Ebo...
...nder drug we are all looking out for. According to...tly increases the cytokine production in cultured...pirulina on the immune system, immunologists at UC...ected blood samples from 12 healthy volunteers and...
Other Medicine News:
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: